Latest News on WST

Financial News Based On Company


Advertisement
Advertisement

GE HealthCare Wins FDA Nod for AI Feeding Tube Detection Software

https://www.tradingview.com/news/zacks:132ba9951094b:0-ge-healthcare-wins-fda-nod-for-ai-feeding-tube-detection-software/
GE HealthCare has received FDA 510(k) clearance for Critical Care Suite 3.0, an AI-enabled software designed to assist clinicians in assessing feeding tube placement through X-ray imaging for both adult and pediatric patients. This innovation enhances GE HealthCare's AI imaging solutions, improving clinical workflows and strengthening its competitive position in the medical imaging market. The software offers high sensitivity for tube detection and operates directly on mobile X-ray devices, providing bedside insights without cloud connectivity.

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:90ea25966094b:0-here-s-why-you-should-retain-neuropace-stock-in-your-portfolio-for-now/
NeuroPace (NPCE) is positioned for long-term growth due to expanding RNS adoption, broader referral networks, improved reimbursement, and potential indication expansions. Despite recent underperformance with shares declining 46.7% year-to-date and a lowered 2026 revenue guidance, factors like physician interest, remote care, and potential market expansion into IGE and adolescent epilepsy offer future opportunities. However, commercial execution challenges and regulatory uncertainties remain near-term hurdles.

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

https://www.theglobeandmail.com/investing/markets/stocks/ISRG/pressreleases/8919202/reasons-to-add-west-pharmaceutical-stock-to-your-portfolio-now/
West Pharmaceutical Services, Inc. (WST) is recommended for addition to portfolios due to strong demand for high-value components (HVPs), increasing exposure to biologics, and regulatory-driven Annex 1 conversions. Despite concerns like tariff pressures and issues at West Vantage, the company has seen a significant stock gain year-to-date and anticipates strong earnings growth. Key growth drivers include demand for GLP-1 and non-GLP-1 related HVPs, regulatory upgrades, and expanding HVP delivery device portfolios.

Philips Unveils Skylight Device Manager to Boost Ultrasound Efficiency

https://www.tradingview.com/news/zacks:0520b01fe094b:0-philips-unveils-skylight-device-manager-to-boost-ultrasound-efficiency/
Philips has introduced Skylight Device Manager, a new cloud-based application providing centralized visibility into connected ultrasound systems to help healthcare organizations manage operations and improve service planning. This solution aims to address the need for efficient medical equipment management amid financial pressures and staffing shortages. The company plans to extend Skylight Device Manager to other imaging modalities beyond ultrasound, such as Diagnostic X-ray systems.

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

https://www.tradingview.com/news/zacks:30957353a094b:0-reasons-to-add-west-pharmaceutical-stock-to-your-portfolio-now/
West Pharmaceutical Services (WST) is positioned for growth due to high demand for its high-value components (HVPs) in GLP-1 and biologics therapies, expanding biologics exposure, and regulatory-driven Annex 1 conversions. Despite facing challenges like the roll-off of legacy programs in West Vantage and the SmartDose 3.5 divestiture, the company's strong HVP components business, regulatory upgrades, and HVP delivery devices are expected to drive future revenue. Zacks Investment Research currently rates WST as a Zacks Rank #2 (Buy).
Advertisement

Life sciences tools & services stocks Q3 recap: Benchmarking Illumina

https://www.tradingview.com/news/stockstory:b8fb8dda9094b:0-life-sciences-tools-services-stocks-q3-recap-benchmarking-illumina/
The life sciences tools and services sector experienced a solid Q3, with revenues beating analyst estimates and positive next-quarter guidance, despite a collective share price decline of 3.3% since recent earnings. The article benchmarks Illumina (ILMN), which reported strong Q3 revenues exceeding expectations but saw its stock drop 27.9%. In contrast, Azenta (AZTA) had the best Q3 performance among peers, with its stock rising 20.3% after impressive results.

GE HealthCare Expands Global Research Network for Photon-Counting CT

https://www.theglobeandmail.com/investing/markets/stocks/ISRG/pressreleases/8902678/ge-healthcare-expands-global-research-network-for-photon-counting-ct/
GE HealthCare Technologies Inc. announced an expansion of its global clinical and research collaborations for Photonova Spectra, its next-generation photon-counting CT system. Seven leading institutions in North America, Europe, and Asia will evaluate the technology across various clinical applications. This initiative aims to generate clinical evidence, support broader adoption, and advance early disease detection and personalized treatment.

GE HealthCare Expands Global Research Network for Photon-Counting CT

https://www.tradingview.com/news/zacks:6158e7bf6094b:0-ge-healthcare-expands-global-research-network-for-photon-counting-ct/
GE HealthCare has expanded its global research network for its Photonova Spectra photon-counting CT system, collaborating with seven leading institutions in North America, Europe, and Asia. This initiative follows regulatory clearances and aims to generate clinical evidence across various applications, enhancing diagnostic capabilities and supporting early disease detection. The move is expected to strengthen GE HealthCare's position in the advanced medical imaging market, with the global photon-counting CT market projected for significant growth.

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:de10b341b094b:0-here-s-why-you-should-retain-opk-stock-in-your-portfolio-for-now/
OPKO Health (OPK) is positioned for growth due to its strengthening Global Products business, contributions from partnered products like NGENLA and mazdutide, and progress in its broad clinical pipeline. Despite these positive factors, the company faces risks including clinical and regulatory hurdles, pressures on partner-product economics, and slow expansion of RAYALDEE in China. Analysts maintain a Zacks Rank #3 (Hold) on the stock, with a positive estimate revision trend for 2026.

Ecolab Launches Integrated Cooling Platform to Tap AI Growth

https://www.tradingview.com/news/zacks:bb44ecc7c094b:0-ecolab-launches-integrated-cooling-platform-to-tap-ai-growth/
Ecolab recently introduced an integrated cooling platform designed for AI data centers, aiming to enhance computing performance and improve water and energy efficiency. The platform combines CoolIT's direct liquid cooling hardware with Ecolab's fluid management expertise and digital technology, including 3D TRASAR. This initiative is expected to strengthen Ecolab's position in the rapidly expanding AI infrastructure market, supporting its goal of reaching $4 billion in High-Tech sales by 2030.
Advertisement

Here's Why You Should Add GEHC Stock to Your Portfolio Right Now

https://www.theglobeandmail.com/investing/markets/stocks/ISRG/pressreleases/8877395/heres-why-you-should-add-gehc-stock-to-your-portfolio-right-now/
GE HealthCare Technologies, Inc. (GEHC) is identified as a strong buy due to its record backlog, robust order momentum, and growth in its Pharmaceutical Diagnostics business, coupled with an expanding pipeline of AI-enabled innovations. Despite facing risks from inflationary pressures and tariff uncertainties, the company shows promising operational recovery in Patient Care Solutions and strong new product innovation. Management has also raised its full-year adjusted EBIT margin and EPS outlook, reflecting confidence in sustained operational improvements.

Here's Why You Should Retain PHG Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:aeb3130a9094b:0-here-s-why-you-should-retain-phg-stock-in-your-portfolio-for-now/
Koninklijke Philips (PHG) is positioned for growth due to strong order momentum in its imaging, image-guided therapy, and monitoring platforms, along with innovation in Personal Health products. Despite challenges like ultrasound manufacturing delays, pricing pressure from China, and inflation, the company's equipment order intake, broad-based growth in Personal Health, and increasing adoption of Monitoring-as-a-Service indicate positive prospects. Analysts maintain a "Hold" rating, and the stock has outperformed the industry year-to-date.

Form 4 West Pharmaceutical Services Inc: Annette F. Favorite (Sr. VP & Chief HR Officer) For: 11 September

https://ca.investing.com/news/stock-market-news/form-4-west-pharmaceutical-services-inc-annette-f-favorite-sr-vp--chief-hr-officer-for-11-september-93CH-4959358
This article reports a Form 4 filing for West Pharmaceutical Services Inc, detailing an insider transaction by Annette F. Favorite, Senior VP & Chief HR Officer. The filing pertains to activity on September 11. The article itself is a brief notification of this public record.

West Pharma sr. VP & chief HR officer sells $2.67M in stock By Investing.com

https://in.investing.com/news/stock-market-news/west-pharma-sr-vp--chief-hr-officer-sells-267m-in-stock-93CH-5705448
Annette F. Favorite, Sr. VP & Chief HR Officer at West Pharmaceutical Services Inc. (NASDAQ:WST), recently sold 7,524 shares of company common stock for approximately $2.67 million. Concurrently, she acquired an equivalent number of shares through stock option exercises valued at $674,451. Following these transactions, Ms. Favorite directly holds 21,817.8098 shares of the company's common stock.

Form 4 West Pharmaceutical Services Inc: Annette F. Favorite (Sr. VP & Chief HR Officer) For: 11 September

https://au.investing.com/news/stock-market-news/form-4-west-pharmaceutical-services-inc-annette-f-favorite-sr-vp--chief-hr-officer-for-11-september-93CH-4771857
This article reports a Form 4 filing for West Pharmaceutical Services Inc. concerning Annette F. Favorite, the Senior Vice President and Chief HR Officer. The filing is dated for September 11th. The article also includes current stock market data, commodity prices, and other financial indices.
Advertisement

West Pharma sr. VP & chief HR officer sells $2.67M in stock

https://ca.investing.com/news/stock-market-news/west-pharma-sr-vp--chief-hr-officer-sells-267m-in-stock-93CH-4959355
Annette F. Favorite, Sr. VP & Chief HR Officer at West Pharmaceutical Services Inc. (NASDAQ:WST), recently sold 7,524 shares of company stock for approximately $2.67 million between September 11 and September 15, 2026. Concurrently, she acquired an equal number of shares by exercising stock options valued at $674,451. Following these transactions, Ms. Favorite directly holds 21,817.8098 shares and no derivative securities.

West Pharma sr. VP & chief HR officer sells $2.67M in stock

https://au.investing.com/news/stock-market-news/west-pharma-sr-vp--chief-hr-officer-sells-267m-in-stock-93CH-4771855
Annette F. Favorite, Sr. VP & Chief HR Officer at West Pharmaceutical Services Inc. (NASDAQ:WST), recently sold 7,524 shares of company common stock for approximately $2.67 million. Concurrently, she acquired 7,524 shares through stock option exercises for $674,451. Following these transactions, Ms. Favorite directly holds 21,817.8098 shares of the company.

West Pharmaceutical to Address Investors at London Conference

https://www.mychesco.com/a/news/business/public-companies/west-pharmaceutical-to-address-investors-at-london-conference/
West Pharmaceutical Services Inc. (NYSE: WST) will present at the Jefferies Global Healthcare Conference in London on November 18, 2026, at 8 a.m. GMT. The Exton-based company, a major manufacturer of injectable drug components with $3.07 billion in annual sales, will offer insights into its global operations to investors and analysts. A live audio webcast and replay will be available through the company's website.

Keith Meister Sells $61M Of Illumina Stock As Shares Slip Below Sale Price

https://www.benzinga.com/trading-ideas/insider-trades/26/11/63249108/keith-meister-sells-61m-of-illumina-stock-as-shares-slip-below-sale-price
Keith Meister of Corvex Management sold 280,091 shares of Illumina Inc (NASDAQ:ILMN) for $61.1 million on November 9, 2026. The sale occurred at a weighted-average price of $218.12 per share, and Illumina's stock subsequently slipped to $208.85, 4.25% below the sale price. Meister significantly reduced his holdings but still beneficially owned 215,713 shares after the transaction.

GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

https://finance.yahoo.com/healthcare/articles/ge-healthcare-forms-magnus-neuro-153600071.html
GE HealthCare Technologies Inc. (GEHC) announced the formation of the MAGNUS Neuro Alliance, a research network dedicated to advancing neuroscience using its ultra-high-gradient, head-only 3.0T MR system. This alliance aims to foster collaboration among leading researchers and clinicians, exploring advanced MRI techniques and developing novel imaging biomarkers for neurological conditions. The initiative seeks to translate scientific breakthroughs into improved patient outcomes, with participating institutions including major universities and hospitals worldwide.
Advertisement

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:9f00fe986094b:0-here-s-why-you-should-retain-dexcom-stock-in-your-portfolio-for-now/
DexCom (DXCM) is positioned for growth due to the potential of the continuous glucose monitoring (CGM) market, strong performance in 2026, and international expansion. Key drivers include the adoption of its G7 15 Day System, manufacturing efficiencies, a European direct distribution strategy, and Smart Basal technology. However, risks like PBM formulary changes, initial margin pressure from the Ireland facility ramp-up, and rising investment requirements could temper operating leverage.

Can West Pharmaceutical Services (WST) Justify Its Price With Cash Flow?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/can-west-pharmaceutical-services-wst-justify-its-price-with
West Pharmaceutical Services (WST) has seen its stock price rise 54.7% over the past year, prompting questions about whether its current valuation is justified by its cash flow. While the company generated $326.7 million in free cash flow over the last twelve months, Discounted Cash Flow (DCF) projections suggest the estimated intrinsic value is meaningfully below the current trading price of $411.30. This indicates the market is placing a premium on future execution and durability of cash flows beyond what models currently support, though analyst consensus considers the stock 13% undervalued based on growth and margin expansion expectations.

West Pharmaceutical Services (WST) Stock May Be 29% Overvalued On Cash Flow Views

https://ca.finance.yahoo.com/news/west-pharmaceutical-services-wst-stock-121409925.html
West Pharmaceutical Services (WST) stock, after a 54.7% return over the past year, appears to be overvalued by approximately 29% based on discounted cash flow (DCF) analysis. While the company's business model supports steady cash generation, the current share price of $411.30 significantly exceeds the DCF outcome, suggesting the market has already priced in much of its future potential. However, Simply Wall St's analyst consensus narrative indicates the stock could be 13% undervalued, contingent on successful execution of higher-margin opportunities.

Here's Why You Should Retain AMN Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:e15112bb5094b:0-here-s-why-you-should-retain-amn-stock-in-your-portfolio-for-now/
AMN Healthcare Services, Inc. (AMN) is expected to grow due to strong demand in nurse and allied staffing, opportunities in Managed Services Programs (MSPs), and investments in technology. Despite these positives, the company faces headwinds from pricing pressure, competitive challenges, visa appointment delays for international nurses, and weakness in its Physician and Technology businesses. Analysts project significant earnings growth for 2026, and the stock has outperformed the industry year-to-date.

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:bcb1fc627094b:0-here-s-why-you-should-retain-conmed-stock-in-your-portfolio-for-now/
CONMED Corporation (CNMD) is recommended for retention in portfolios due to strong growth drivers such as the adoption of AirSeal, Buffalo Filter, and BioBrace platforms. The company benefits from rising robotic procedure volumes and expanding Ambulatory Surgery Centers, with its stock outperforming the industry and S&P 500. However, challenges include U.S. Orthopedic weakness, volatility in OEM Buffalo Filter sales, and less predictable international growth due to distributor order timing.
Advertisement

GEHC Expands Vscan Air AI Capabilities With Lung Guidance & AutoAS

https://www.theglobeandmail.com/investing/markets/stocks/ISRG/pressreleases/8765594/gehc-expands-vscan-air-ai-capabilities-with-lung-guidance-autoas/
GE HealthCare Technologies Inc. (GEHC) has enhanced its Vscan Air handheld ultrasound system with two new AI-assisted capabilities: Lung Guidance and AutoAS. These tools are designed to streamline lung ultrasound image acquisition and aid in assessing moderate-to-severe aortic stenosis at the point of care. The expansion of its cardiopulmonary AI suite aims to help clinicians make more informed decisions, especially when access to formal imaging or specialist interpretation is limited, potentially strengthening GE HealthCare's position in the point-of-care ultrasound market.

Bancorp Targets Higher Earnings as Fintech Lending Expands

https://www.mychesco.com/a/news/regional/bancorp-targets-higher-earnings-as-fintech-lending-expands/
The Bancorp Inc. reported a significant increase in third-quarter earnings per share, projecting further gains through 2028 driven by expanding fintech lending and payment activities. The company's strategy includes major fintech initiatives, operational improvements through restructuring and AI, and continued share repurchases, offsetting declining interest margins. Fintech loans and fees are growing rapidly, while the company maintains strong capital ratios despite shifts in its balance sheet composition.

How Investors Are Reacting To West Pharmaceutical Services Stock After Raised Outlook

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/how-investors-are-reacting-to-west-pharmaceutical-services-s
West Pharmaceutical Services reported strong Q3 2026 results with sales of US$874.5 million and net income of US$214 million, leading to a raised full-year net sales guidance of US$3.41 billion to US$3.42 billion and diluted EPS of US$9.31 to US$9.41. The company also announced US$685.26 million in share repurchases and a higher Q4 dividend, reflecting management's confidence in demand for high-value packaging components. The investment narrative now focuses on how this raised outlook and capital returns compare with peers and the smooth transition of contract manufacturing into GLP-1 and drug handling programs.

West Pharmaceutical stock gets higher 2026 outlook after Q3 growth

https://www.ad-hoc-news.de/boerse/news/corporate-news/west-pharmaceutical-stock-gets-higher-2026-outlook-after-q3-growth/70477374
West Pharmaceutical Services raised its full-year 2026 sales and adjusted earnings outlook after reporting strong third-quarter results driven by demand for high-value product components. The company now expects net sales between USD 3.41 billion and USD 3.42 billion and adjusted diluted EPS of USD 9.38 to USD 9.48. Additionally, management lowered its capital spending forecast for the year.

West Pharmaceutical Services (WST) Raises 2026 Outlook On Earnings Strength As Fair Value Debate Builds

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/west-pharmaceutical-services-wst-raises-2026-outlook-on-earn
West Pharmaceutical Services (WST) reported strong third-quarter results, including higher sales and net income, leading to an upgraded 2026 outlook and share repurchases. The company's stock has seen significant short-term gains, with a 30-day return of 9.09% and a year-to-date return of 44.65%. While analysts suggest the stock is 15% undervalued with a fair value of $471, its P/E ratio of 43.6x is above the industry average and an estimated fair ratio of 24.5x, raising questions about its current valuation.
Advertisement

Here's Why You Should Retain MMSI Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:8e0b135ea094b:0-here-s-why-you-should-retain-mmsi-stock-in-your-portfolio-for-now/
Merit Medical Systems, Inc. (MMSI) is positioned for growth due to its strong product portfolio, global expansion, and strategic acquisitions, despite challenges from China market pressures and gross margin headwinds. The company delivered an average earnings surprise of 13% over the past four quarters and projects 10.6% growth for the next five years. While product innovation and clinical evidence contribute to its expansion, competitive pressure and tariff-related costs remain concerns.

West Pharmaceutical Raises Outlook as Earnings Surge 57%

https://www.mychesco.com/a/news/business/finance/west-pharmaceutical-raises-outlook-as-earnings-surge-57/
West Pharmaceutical Services Inc. (NYSE: WST) has raised its full-year 2026 sales and earnings forecasts after a significant 57.3% surge in third-quarter profit. This growth was primarily fueled by robust demand for high-value pharmaceutical packaging components, leading to increased revenue and expanded operating margins. The company's Proprietary Products segment, particularly high-value components, was the main driver of this strong performance.

Two holders report the same 8.5% stake in West Pharmaceutical (WST).

https://www.stocktitan.net/sec-filings/WST/schedule-13g-a-west-pharmaceutical-services-inc-amended-passive-inves-05c335ed8e8f.html
FMR LLC and Abigail P. Johnson have each reported an 8.5% beneficial ownership stake in West Pharmaceutical Services Inc. (WST), totaling 5,962,737.88 shares. FMR LLC holds sole voting power over a majority of these shares, while Abigail P. Johnson has sole dispositive power over all reported shares. The filing indicates that no other person's interest exceeds 5% of WST's outstanding common stock.

Tyler Technologies, Inc. (TYL) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/TYL/
Tyler Technologies, Inc. (TYL) is currently trading at $426.11, showing a slight increase of 0.69%. The company, which provides integrated software and technology management solutions for the public sector, has a market cap of $16.942 billion and a P/E ratio of 53.08. Recent analyst ratings include a "Neutral" rating from Goldman Sachs, with a raised price target of $385.

A London healthcare conference talk featuring West Pharmaceutical will be available live online Nov. 18.

https://www.stocktitan.net/news/WST/west-to-participate-in-upcoming-investor-jo8eiutnmc71.html
West Pharmaceutical Services (NYSE: WST) announced its participation in the Jefferies Global Healthcare Conference in London on November 18, 2026, at 8:00 a.m. GMT. A live audio webcast of the presentation will be available on the company's website, with a replay accessible for approximately 90 days. The company, a global leader in injectable drug administration solutions, generated $3.07 billion in net sales in fiscal year 2025.
Advertisement

Tyler Technologies, Inc. (TYL) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4312_QuantitativeReport_1792540800000
Tyler Technologies, Inc. (TYL) has received an upgraded price target of $415.00 from Argus, as reported on October 21, 2026. The company, which provides software solutions and services to local government entities, is currently trading at $404.24. This report indicates a positive outlook from analysts.

West Pharmaceutical stock: 2026 outlook rises after Q3 growth

https://www.ad-hoc-news.de/boerse/news/corporate-news/west-pharmaceutical-stock-2026-outlook-rises-after-q3-growth/70450549
West Pharmaceutical Services has raised its full-year 2026 revenue and adjusted earnings outlook following stronger third-quarter results. The company now expects revenue between USD 3.41 billion and USD 3.42 billion, with adjusted earnings per share between USD 9.38 and USD 9.48. This positive revision is driven by an 8.7 percent increase in third-quarter revenue and higher net income.

West Pharmaceutical Services Inc. stock underperforms Monday when compared to competitors

https://www.marketwatch.com/data-news/west-pharmaceutical-services-inc-stock-underperforms-monday-when-compared-to-competitors-f8848733-a012d6f9a100?mod=mw_quote_news
Shares of West Pharmaceutical Services Inc. (WST) fell 1.15% on Monday, underperforming a mixed trading session where the Dow Jones Industrial Average rose and the S&P 500 Index declined. This marked the stock's second consecutive day of losses.

WST Q3 deep dive: Biologics and regulatory tailwinds fuel margin expansion, HVP mix shift continues

https://stockstory.org/us/stocks/nyse/wst/news/earnings-call/wst-q3-deep-dive-biologics-and-regulatory-tailwinds-fuel-margin-expansion-hvp-mix-shift-continues
West Pharmaceutical Services (WST) announced better-than-expected Q3 2026 results, with revenue up 8.7% year-on-year to $874.5 million and adjusted EPS exceeding estimates. The company raised its full-year guidance, driven by strong demand for high-value product (HVP) components, especially in biologics and GLP-1 therapies, and ongoing regulatory upgrades. Management highlighted operational improvements, international expansion, and a record pipeline of biologic drugs as key factors supporting continued growth and margin expansion.

West Pharmaceutical Services (WST) Stock Looks Rich Against Its Cash Flow

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/west-pharmaceutical-services-wst-stock-looks-rich-against-it
West Pharmaceutical Services (WST) stock has seen a significant 49.3% increase year-to-date, reaching US$412.62, prompting a review of its valuation against cash flows. A Discounted Cash Flow (DCF) model suggests the stock's current price is meaningfully above its intrinsic value based on projected free cash flow, despite strong Q3 2026 results and raised full-year guidance. The article explores what future revenue and profitability trends would be needed to justify the current market price, according to Simply Wall St Narratives.
Advertisement

UFP Technologies (UFPT) Q3 earnings report preview: what to look for

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-2-ufp-technologies-ufpt-q3-earnings-report-preview-what-to-look-for
UFP Technologies (NASDAQ: UFPT) is set to announce its Q3 earnings results, with analysts expecting an 8.1% year-on-year revenue growth. The medical products company has a history of beating revenue expectations but has also missed Wall Street's estimates multiple times in the past two years. Investors will be watching closely as other drug development inputs & services segment peers have shown mixed results.

How Investors Are Reacting To West Pharma Shares After Raised Guidance

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-wst/west-pharmaceutical-services/news/how-investors-are-reacting-to-west-pharma-shares-after-raise
West Pharmaceutical Services reported strong Q3 2026 results, including higher sales and net income, and raised its full-year 2026 guidance. This performance, coupled with a higher dividend and a new multi-currency credit facility, suggests the company is effectively combining earnings momentum with financial flexibility and shareholder returns. Investors are now evaluating how this raised outlook and strategic financial moves might influence the company's investment narrative, particularly its shift towards higher-value components and effective debt deployment.

Teleflex Secures FDA Breakthrough Status for Heart Device

https://www.mychesco.com/a/news/health-medical/teleflex-secures-fda-breakthrough-status-for-heart-device/
Teleflex Incorporated has received FDA Breakthrough Device Designation for its Freesolve Resorbable Magnesium Scaffold for coronary artery procedures. This designation is intended to expedite the regulatory review process for the device, which is already available internationally. Teleflex is currently conducting a pivotal clinical trial to support future U.S. market approval for this temporary vascular implant.

West Pharmaceutical Services, Inc. (WST) Seasonal returns chart

https://uk.finance.yahoo.com/quote/WST/seasonality/
This article provides a seasonal returns chart for West Pharmaceutical Services, Inc. (WST), showing the average monthly price return between 2016 and 2026. It also includes current stock information, recent earnings call details, and related tickers, as part of Yahoo Finance's data.

West Pharmaceutical Services Inc (WPS.SG) Seasonal returns chart

https://uk.finance.yahoo.com/quote/WPS.SG/seasonality/
The article provides a seasonal returns chart for West Pharmaceutical Services Inc (WPS.SG), showing the average monthly price return between 2017 and 2026. It also includes the latest stock quote and information about the company's Q3 2026 earnings call. The content is presented within the Yahoo Finance platform, alongside general market data.
Advertisement

IDeutsche Bank Adjusts West Pharmaceutical Services PT to $450 From $420, Maintains Buy Rating

https://finance.yahoo.com/markets/stocks/articles/deutsche-bank-adjusts-west-pharmaceutical-123928706.html
IDeutsche Bank has increased its price target for West Pharmaceutical Services (WST) to $450 from $420, while reiterating a "Buy" rating on the stock. West Pharmaceutical Services currently holds an average "Buy" rating and a mean price target of $467.14 across analysts. The article, originally published by MT Newswires, also notes the company's stock symbol and a slight decrease in its share price at the time of publication.

West Pharmaceutical Services, Inc. Stock 12‑Month Price Target Raised to $470, Implies 13% Upside

https://www.tradingview.com/news/tradingview:5d8f94cffbd11:0-west-pharmaceutical-services-inc-stock-12-month-price-target-raised-to-463-57-implies-11-upside/
The average 12-month price target for West Pharmaceutical Services, Inc. (WST) stock has been raised from $465 to $470 by 14 analysts, implying a 13% potential upside from its Oct. 29 closing price. The consensus rating among 19 analysts remains a "Buy," with 18 recommending a buy and only 1 recommending a sell.

West Pharmaceutical Services, Inc. Stock 12‑Month Price Target Raised to $470, Implies 13% Upside

https://www.tradingview.com/news/tradingview:5d8f94cffbd11:0-west-pharmaceutical-services-inc-stock-12-month-price-target-raised-to-470-implies-13-upside/
The average 12-month price target for West Pharmaceutical Services, Inc. (WST) stock has increased from $465 to $470, with analysts' forecasts ranging from $400 to $500 per share. This updated target suggests a potential upside of approximately 13% based on the Oct. 29 closing price. The consensus analyst rating remains a "Buy" from 19 covering analysts.

West Pharmaceutical Services, Inc. Stock 12‑Month Price Target Raised to $427.57, Implies 6% Upside

https://www.tradingview.com/news/tradingview:7fe321cf1ca28:0-west-pharmaceutical-services-inc-stock-12-month-price-target-raised-to-427-57-implies-6-upside/
The average 12-month price target for West Pharmaceutical Services, Inc. (WST) stock has increased to $427.57 from $421.86, according to estimates from 14 analysts. This updated target implies approximately 6% potential upside based on the Oct. 28 closing price. The consensus rating among 19 covering analysts remains "Buy," with 18 Buys, 0 Holds, and 1 Sell recommendation.

West Pharmaceutical Services 3Q 2026: Revenue $874.5M, EPS $3.02— 10-Q Summary

https://www.tradingview.com/news/tradingview:17b65d83a0e06:0-west-pharmaceutical-services-3q-2026-revenue-874-5m-eps-3-02-10-q-summary/
West Pharmaceutical Services reported strong third-quarter 2026 results with revenue of $874.5 million and diluted EPS of $3.02, reflecting significant year-over-year growth. The company saw robust organic sales, particularly in Proprietary Products driven by biologics and GLP-1 demand, despite a decline in West Vantage sales due to a contract expiration and a cyber incident. Management anticipates no material impact from tariffs or Middle East developments.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement